natgillin/translations-raw huggingface dataset:
Post-Menopausal *a hazard ratio (TAC/FAC) of less than 1 indicates that TAC is associated with a longer disease free survival compared to FAC. 
Postmenopauza * omjer rizika (TAC/FAC) manji od 1 prikazuje da je TAC povezan sa dužim preživljenjem bez znakova bolesti u usporedbi sa FAC-om.
very common (≥1/10), common (≥1/100 to < 1/10); uncommon (≥1/1,000 to < 1/100); rare (≥1/10,000 
Učestalosti su definirane kao: vrlo često (≥1/10); često (≥1/100 i <1/10); manje često (≥1/1000 i <1/100); rijetko (≥1/10 000 i <1/1000); vrlo rijetko (<1/10 000); nepoznato (učestalost se ne može procijeniti iz dostupnih podataka).
In study TAX316, 26 patients (3.5%) in the TAC arm and 17 patients (2.3%) in the FAC arm experienced congestive heart failure. 
U studiji TAX 316, 26 bolesnika (3,5%) u TAC skupini te 17 bolesnika (2,3%) u FAC skupini doživjelo je kongestivno zatajivanje srca (CHF).
administered over 6-10 minutes on days 1, 8, 15, 22 followed by cisplatin 100 mg/m administered on day 1 of cycles repeated every 4 weeks (VCis). 
do 10 minuta na dan 1, 8, 15, 22, nakon čega je slijedilo davanje cisplatine 100 mg/m2 na dan 1 ciklusa koji se ponavljao svaka 4 tjedna (VCis).
Symptoms such as early abdominal pain and tenderness, fever, diarrhoea, with or without neutropenia, may be early manifestations of serious gastrointestinal toxicity and should be evaluated and treated promptly. 
Gastrointestinalne reakcije Simptomi poput rane pojave boli u abdomenu i osjetljivosti na dodir, vrućice, proljeva s ili bez neutropenije, mogu biti rani znaci teške gastrointestinalne toksičnosti koju treba brzo procijeniti i liječiti.
Efficacy results are summarized in the following table: 
Rezulatati djelotvornosti sažeti su u sljedećoj tablici:
A hazard ratio of less than 1 favours docetaxel + cisplatin + 5-FU *Cox model (adjustment for Primary tumour site, T and N clinical stages and PSWHO) **Log rank test *** Chi-square test 
Omjer rizika manji od 1 daje prednost kombinaciji docetaksel + cisplatin + 5-FU * Coxov model (prilagodba prema primarnom mjestu tumora, T i N kliničkim stadijima te PSWHO)
In GEICAM 9805 study, 3 patients (0.6%) in TAC arm and 3 patients (0.6%) in FAC arm developed congestive heart failure during the follow-up period. 
U studiji GEICAM 9805, 3 bolesnika (0,6%) u TAC skupini i 3 bolesnika (0,6 %) u FAC skupini razvilo je kongestivno zatajenje srca tijekom perioda praćenja.
The most commonly reported adverse reactions of Docetaxel Teva alone are: decrease in the number of red blood cells or white blood cells, alopecia, nausea, vomiting, sores in the mouth, diarrhoea and tiredness. 
Najčešće prijavljivane nuspojave Docetaksel Teva kada se primjenjuje sam su: pad broja crvenih ili bijelih krvnih stanica, alopecija, mučnina, povraćanje, ranice u ustima, proljev i umor.
Based on pharmacokinetic data with docetaxel at 100 mg/m² as single agent, patients who have both elevations of transaminase (ALT and/or AST) greater than 1.5 times the upper limit of the normal range (ULN) and alkaline phosphatase greater than 2.5 times the ULN, the recommended dose of docetaxel is 75 mg/m2 (see sections 4.4 and 5.2). 
Prema farmakokinetičkim podacima za monoterapiju docetakselom u dozi od 100 mg/m2, za bolesnike koji imaju povišene vrijednosti transaminaza (ALT i/ili AST) više od 1,5 puta od gornje granice normalnih vrijednosti (GGN) i alkalne fosfataze više od 2,5 puta od GGN, preporučena doza docetaksela je 75 mg/m2 (vidjeti dio 4.4. i 5.2).
If you are a man being treated with Docetaxel Teva you are advised not to father a child during and up to 6 months after treatment and to seek advice on conservation of sperm prior to treatment because docetaxel may alter male fertility. 
Muškarcima koji primaju Docetaksel Teva savjetuje se da ne začinju dijete tijekom liječenja i do 6 mjeseci nakon prestanka terapije te da potraže savjet o konzervaciji sperme prije liječenja, jer docetaksel može utjecati na plodnost muškarca.
Docetaxel Teva has been prescribed by your doctor for the treatment of breast cancer, special forms of lung cancer (non-small cell lung cancer), prostate cancer, gastric cancer or head and neck cancer: - For the treatment of advanced breast cancer, Docetaxel Teva could be administered either alone or in combination with doxorubicin, or trastuzumab, or capecitabine. 
Docetaksel Teva Vam je propisao liječnik za liječenje karcinoma dojke, posebnih oblika karcinoma pluća (karcinom nemalih stanica pluća), karcinoma prostate, karcinoma želuca ili karcinoma glave i vrata: - Za liječenje uznapredovalog karcinoma dojke, Docetaksel Teva se primjenjuje sam ili u kombinaciji s doksorubicinom, trastuzumabom ili kapecitabinom.
Severe nail disorders are characterised by hypo- or hyperpigmentation and sometimes pain and onycholysis. 
Teške promjene na noktima karakterizirali su hipo- ili hiperpigmentacijom ponekad praćene boli i oniholizom.
This leaflet was last revised in {MM/YYYY} Other sources of information 
Ova uputa je zadnji puta revidirana u {MM/GGGG}
In combination with cisplatin For patients who are dosed initially at docetaxel 75 mg/m2 in combination with cisplatin and whose nadir of platelet count during the previous course of therapy is <25,000 cells/mm3, or in patients who experience febrile neutropenia, or in patients with serious non-haematologic toxicities, the docetaxel dose in subsequent cycles should be reduced to 65 mg/m2. 
Bolesnicima koji početnu dozu docetaksela od 75 mg/m2 primaju u kombinaciji s cisplatinom i u kojih je najniži broj trombocita tijekom prethodnog ciklusa liječenja iznosio < 25.000 stanica/mm3, u bolesnika koji su imali febrilnu neutropeniju ili u bolesnika s ozbiljnim nehematološkim toksičnim učincima, doza docetaksela u sljedećim ciklusima mora se smanjiti na 65 mg/m2.
More than one premix vial may be necessary to obtain the required dose for the patient. 
Ponekad je potrebno upotrijebiti više od jedne bočice s pripremljenom otopinom koncentrata kako bi se dobila potrebna doza za bolesnika.
How to store Docetaxel Teva 
Kako čuvati Docetaksel Teva
• For patients developing the second appearance of Grade 2 toxicity, or the first appearance of Grade 3 toxicity, at any time during the treatment cycle, delay treatment until resolved to Grade 0-1 and then resume treatment with docetaxel 55 mg/m². 
• Bolesnicima u kojih se drugi put pojavila toksičnost stupnja 2, ili u kojih se prvi put pojavila toksičnost stupnja 3, u bilo koje vrijeme liječenja, treba odgoditi terapiju sve dok se ne postigne stupanj toksičnosti 0-1, a nakon toga nastaviti liječenje docetakselom 55 mg/m2.
Docetaxel was administered as a 1-hour infusion, all other medicinal products were given intraveinously on day 1 every three weeks. 
Docetaksel se primjenjivao u obliku jednosatne infuzije, a svi ostali lijekovi davali su se intravenski na dan 1 svaka tri tjedna.
• alteration in sense of taste 
• glavobolja • promjene osjeta okusa
• redness and swelling of the palms of your hands or soles of your feet which may cause your skin to peel (this may also occur on the arms, face, or body) 
• crvenilo i oticanje dlanova ili tabana koje može uzrokovati ljuštenje kože (ovo se može također pojaviti na rukama, licu ili tijelu) • promjena boje noktiju koji nakon toga mogu otpasti
Among the 300 (221 patients in the phase III part of the study and 79 patients in the phase II part) patients treated with docetaxel in combination with cisplatin and 5-fluorouracil in the gastric cancer study, 74 were 65 years of age or older and 4 patients were 75 years of age or older. 
Od 300 bolesnika (221 bolesnik u fazi III ispitivanja i 79 bolesnika u fazi II ispitivanja) liječenih s docetakselom u kombinaciji s cisplatinom i 5-fluoruracilom u studiji koja je uključivala bolesnike s karcinomom želuca, njih 74 je bilo u dobi od 65 godina ili starijih, a 4 ih je bilo u dobi od 75 godina ili starijih.
Obligation to conduct post-authorisation measures Not applicable 
• Obaveza provođenja mjera nakon davanja odobrenja
• For patients developing the first appearance of Grade 2 toxicity, which persists at the time of the next docetaxel/capecitabine treatment, delay treatment until resolved to Grade 0-1, and resume at 100% of the original dose. 
• Bolesnicima u kojih se prvi put pojavila toksičnost stupnja 2, a prisutna je i u vrijeme sljedećeg ciklusa liječenja kombinacijom docetaksel/kapecitabin, treba odgoditi liječenje dok se ne postigne stupanj toksičnosti 0-1, a nakon toga nastaviti sa 100% originalne doze.
Patients must receive premedication with antiemetics and appropriate hydration (prior to and after cisplatin administration). 
Karcinom glave i vrata Bolesnici moraju primiti premedikaciju antiemeticima i biti primjereno hidrirani (prije i poslije primjene cisplatina).
In both arms, after the last cycle of chemotherapy, patients with ER+ and/or PgR+ tumours received tamoxifen 20 mg once a day for up to 5 years. 
U obje skupine, nakon poslijednjeg ciklusa kemoterapije, bolesnici sa ER+ i/ili PgR+ tumorima, primali su tamoksifen 20 mg jednom na dan u razdoblju do 5 godina.
75 to 60 mg/m². 
na 60 mg/m2.
Dry skin; Desquamation 
osip praćen svrbežom suha koža; deskvamacija
Docetaxel Teva vials should not be stored above 25°C and should be protected from light. 
Docetaksel Teva bočice treba čuvati na temperaturi do 25°C, zaštićeno od svjetlosti.
Docetaxel Teva in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck. 
Docetaksel Teva u kombinaciji s cisplatinom i 5-fluorouracilom je indiciran za indukcijsko liječenje bolesnika s lokalno uznapredovalim karcinomom skvamoznih stanica glave i vrata.
• one vial (5.12 ml) of solvent (water for injections). 
• jednu bočicu (5,12 ml) s otapalom (voda za injekcije).
Patients receiving TCF should be closely monitored, (see sections 4.2 and 4.8). 
Bolesnici koji primaju TCF moraju biti pod stalnim nadzorom (vidjeti dio 4.2 i 4.8).
There is no relevant use of Docetaxel Teva in the paediatric population in the indications breast cancer, non-small cell lung cancer, prostate cancer, gastric carcinoma and head and neck cancer, not including type II and III less differentiated nasopharyngeal carcinoma. 
Nema relevantne primjene Docetaksela Teva u pedijatrijskoj populaciji za indikacije karcinoma dojke, karcinoma nemalih stanica pluća, karcinoma prostate, karcinoma želuca i karcinoma glave i vrata, ne uključujući manje diferencirani nazofaringealni karcinom tipa II i III.
After 10 years of follow-up in GEICAM 9805 study, acute leukaemia occurred in 1 of 532 (0.2%) patients. 
Nakon 10 godina praćenja u GEICAM 9805 studiji akutna leukemija pojavila se u 1 od 532 bolesnika (0,2%) u TAC skupini.
This volume has been established during the development of docetaxel to compensate for liquid loss during preparation of the premix (see section 4) due to foaming, adhesion to the walls of the vial and "dead-volume". 
Taj volumen punjenja utvrđen je tijekom razvoja docetaksela kako bi se nadoknadio gubitak tekućine koji nastaje tijekom pripreme otopine koncentrata (vidjeti dio 4), zbog pjenjenja, adhezije za stijenku bočice i neiskoristivog volumena koji zaostaje u bočici.
One TAC patient (0.1%) and 1 FAC patient (0.1%) died due to AML during the follow-up period (median follow-up time of 8 years). 
skupini i 1 bolesnik (0,1%) u FAC skupini preminuli su zbog akutne mijeloične leukemije (AML) tijekom perioda praćenja (medijan vremena praćenja iznosio je 8 godina).
Remove the syringe and needle and mix manually by repeated inversions for at least 45 seconds. 
Uklonite štrcaljku i iglu te ručno promiješajte okretanjem bočice gore-dolje tijekom najmanje 45
In case of Grade 4 thrombocytopenia the docetaxel dose should be reduced from 75 to 60 mg/m2. 
slučaju trombocitopenije stupnja 4 dozu docetaksela treba smanjiti sa 75 na 60 mg/m2.
How to use Docetaxel Teva 
Kako primjenjivati Docetaksel Teva
Docetaxel should be administered when the neutrophil count is ≥1,500 cells/mm3. 
Docetaksel treba primjenjivati kad je broj neutrofila ≥ 1500 stanica/mm3.
The onset of moderate and severe retention is delayed (median cumulative dose: 818.9 mg/m2) in patients with premedication compared with patients without premedication (median cumulative dose: 489.7 mg/m2); however, it has been reported in some patients during the early courses of therapy. 
Pojava umjerene i teške retencije je odgođena (medijan kumulativne doze: 818,9 mg/m2) u bolesnika koji su primili premedikaciju u odnosu na bolesnike koji nisu primili premedikaciju (medijan kumulativne doze:
Hazard ratio: 1.122 [97.2% CI: 0.937; 1.342]* 
Omjer rizika: 1,122 [97,2% CI: 0,937; 1,342]*
Headache (G3/4: <1%); Neuropathy peripheral 
omaglica; glavobolja (G3/4: <1%); periferna neuropatija
It is important that you read the entire contents of this guide prior to the preparation of either the Docetaxel Teva premix solution or the Docetaxel Teva infusion solution 
Važno je pročitati cijeli sadržaj upute prije pripreme Docetaksel Teva otopine koncentrata i
• one vial (2.88 ml) of concentrate (80 mg of docetaxel), 
• jednu bočicu (2,88 ml) s koncentratom (80 mg docetaksela),
CAUTION: Dilution of concentrate required using the entire contents of the solvent vial. 
UPOZORENJE: koncentrat je potrebno razrijediti cjelokupnim sadržajem bočice s otapalom.
H-2100 Gödöllő, Táncsics Mihály út 82 
TEVA Pharmaceutical Works Private Limited Company H-2100 Gödöllő, Táncsics Mihály út 82
Following the administration of a 100 mg/m2 dose given as a one hour infusion a mean peak plasma level of 3.7 μg/ml was obtained with a corresponding AUC of 4.6 h.μg/ml. 
Nakon primjene doze od 100 mg/m2 putem jednosatne infuzije, dobivena je srednja vrijednost vršne razine lijeka u plazmi od 3,7 μg/ml s odgovarajućim AUC-om od 4,6 h μg/ml.
Docetaxel Teva concentrate for solution for infusion is a clear viscous, yellow to brown-yellow solution. 
Docetaksel Teva koncentrat za otopinu za infuziju je prozirna, viskozna, žuta do smeđežuta otopina.
PREPARATION FOR THE INTRAVENOUS ADMINISTRATION 
Za intravensku primjenu
4.1.1 If the vials are stored under refrigeration, allow the required number of Docetaxel Teva boxes to stand at room temperature (below 25°C) for 5 minutes. 
4.1.1 Ako su bočice pohranjene u hladnjaku, izvadite potreban broj kutija Docetaksel Teva iz hladnjaka i ostavite ih na sobnoj temperaturi (ispod 25°C) 5 minuta.
PF). 
PSWHO)
You must not breast-feed while you are treated with Docetaxel Teva. 
Ne smijete dojiti tijekom liječenja Docetaksel Teva.
Both regimens were administered on day 1 every 3 weeks. 
Oba kemoterapijska protokola primjenjivala su se na dan 1 svaka 3 tjedna.
Allow the premix vial to stand for 5 minutes at room temperature (below 25°C) and then check that the solution is homogenous and clear (foaming is normal even after 5 minutes due to the presence of polysorbate 80 in the formulation). 
Ostavite bočicu s pripremljenom otopinom koncentrata na sobnoj temperaturi (ispod 25 oC) oko 5 minuta, a zatim provjerite je li otopina homogena i bistra (pojava pjene je uobičajena i nakon 5 minuta zbog polisorbata 80 u sastavu).
If the vials are stored under refrigeration, allow the required number of Docetaxel Teva boxes to stand at room temperature (below 25°C) for 5 minutes. 
Ako su bočice pohranjene u hladnjaku, izvadite potreban broj kutija Docetaksel Teva iz hladnjaka i ostavite ih na sobnoj temperaturi (ispod 25 oC) 5 minuta.
Docetaxel has been shown to be mutagenic in the in vitro micronucleus and chromosome aberration test in CHO-K1 cells and in the in vivo micronucleus test in the mouse. 
Docetaksel se pokazao mutagenim u in vitro mikronukleusnom testu i testu kromosomske aberacije na
- For the treatment of early breast cancer with or without lymph node involvement, Docetaxel Teva could be administered in combination with doxorubicin and cyclophosphamide. 
Za liječenje ranog karcinoma dojke sa ili bez zahvaćenih limfnih čvorova, Docetaksel Teva se primjenjuje u kombinaciji s doksorubicinom i ciklofosfamidom.
A total of 445 patients with KPS>70 were treated with either docetaxel (T) (75 mg/m2 on day 1) in combination with cisplatin (C) (75 mg/m2 on day 1) and 5-fluorouracil (F) (750 mg/m2 per day for 5 days) or cisplatin (100 mg/m2 on day 1) and 5-fluorouracil (1,000 mg/m2 per day for 5 days). 
Svih 445 bolesnika s KPS >70 liječeni su ili docetakselom (T) (75 mg/m2 prvi dan) u kombinaciji s cisplatinom (C) (75 mg/m2 prvi dan) i 5-fluorouracilom (F) (750 mg/m2 na dan kroz 5 dana) ili cisplatinom (100 mg/m2 prvi dan) i 5-fluorouracilom (1000 mg/m2 na dan kroz 5 dana).
After 10 years of follow up in study TAX316, acute leukaemia was reported in 3 of 744 TAC patients (0.4%) and in 1 of 736 FAC patients (0.1%). 
Nakon 10 godina praćenja u studiji TAX 316, akutna leukemija zabilježena je u 43 od 744 bolesnika (0.4%) u TAC skupini te u 1 od 736 bolesnika (0,1%) u FAC skupini.
• Infusion solution: Chemical and physical in-use stability has been demonstrated for 4 hours at room temperature (below 25°C). 
• Infuzijska otopina: Dokazana kemijska i fizikalna stabilnost u primjeni je 4 sata na sobnoj temperaturi (ispod 25°C).
4.1.4 Remove the syringe and needle and mix manually by repeated inversions for at least 45 seconds. 
4.1.4 Uklonite štrcaljku i iglu te ručno promiješajte okretanjem bočice gore-dolje najmanje 45
In combination with capecitabine, the recommended dose of docetaxel is 75 mg/m2 every three weeks, combined with capecitabine at 1,250 mg/m2 twice daily (within 30 minutes after a meal) for 2 weeks followed by a 1-week rest period. 
U kombinaciji s kapecitabinom, preporučena doza docetaksela je 75 mg/m2 svaka tri tjedna u kombinaciji s kapecitabinom u dozi od 1250 mg/m2 dvaput na dan (unutar pola sata nakon obroka) u trajanju od 2 tjedna, nakon čega slijedi tjedan dana pauze.
The development of severe peripheral neurotoxicity requires a reduction of dose (see sections 4.2 and 4.4). 
Poremećaji živčanog sustava Razvoj teške periferne neurotoksičnosti zahtijeva smanjenje doze (vidjeti dio 4.2 i 4.4).
Docetaxel Teva is an antineoplastic agent and, as with other potentially toxic compounds, caution should be exercised when handling it and preparing Docetaxel Teva solutions. 
Teva je antineoplastična tvar te se, kao što je slučaj i sa svim ostalim potencijalno toksičnim spojevima, mora s njime oprezno rukovati u pripremi otopine Docetaksela.
Table below shows that the incidence of Grade 4 neutropenia, febrile neutropenia and neutropenic infection was decreased in patients who received primary G-CSF prophylaxis after it was made mandatory in the TAC arm - GEICAM study. 
Sljedeća tablica prikazuje da je incidencija neutropenije stupnja 4, febrilne netropenije i neutropenijske infekcije smanjena u bolesnika koji su primali primarnu profilaksu s G-CSF nakon što je ona uvedena kao obavezna u TAC skupini - GEICAM studija.
• one vial of 0.72 ml concentrate (20 mg of docetaxel), 
• jednu bočicu s 0,72 ml koncentrata (20 mg docetaksela),
Febrile neutropenia and neutropenic infection occurred respectively in 12.1% and 3.4% of patients when patients received prophylactic G-CSF, in 15.6% and 12.9% of patients without prophylactic G-CSF, (see section 4.2). 
bolesnika koji su profilaktički primali G-CSF i u 15,6% i 12,9% bolesnika koji nisu profilaktički primali G-CSF (vidjeti dio 4.2).
In patients who experienced either febrile neutropenia, neutrophil count <500 cells/mm for more than one week, severe or cumulative cutaneous reactions or severe peripheral neuropathy during docetaxel therapy, the dose of docetaxel should be reduced from 100 mg/m2 to 75 mg/m2 and/or from 
Bolesnicima koji razviju febrilnu neutropeniju, imaju broj neutrofila manji od 500 stanica/mm dulje od tjedan dana, razviju teške ili kumulativne kožne reakcije ili tešku perifernu neuropatiju tijekom liječenja docetakselom, dozu docetaksela treba smanjiti sa 100 mg/m2 na 75 mg/m2 i/ili sa 75 mg/m2
For treatment after failure of prior platinum-based chemotherapy, the recommended dose is 75 mg/m² as a single agent. 
Za liječenje nakon neuspjeha prethodne kemoterapije temeljene na platini, preporučuje se doza od 75 mg/m2 u monoterapiji.
Second primary malignancies (including acute myeloid leukemia, myelodysplastic syndrome and non-Hodgkin lymphoma) may occur several months or years after docetaxel-containing therapy. 
mijelodisplastični sindrom i ne-Hodgkinov limfom) mogu se javiti nekoliko mjeseci ili godina nakon terapije koja uključuje docetaksel.
There is no information on the use of docetaxel in pregnant women. 
Nema podataka o primjeni docetaksela u trudnica.
in TAC arm. No cases were reported in patients in FAC arm. No patient was diagnosed with myelodysplastic syndrome in either treatment groups. 
Niti jednom bolesniku u obje skupine nije dijagnosticiran mijelodisplastični sindrom.
One large randomised phase III study, involving 429 previously untreated patients with metastatic disease, has been performed with doxorubicin (50 mg/m²) in combination with docetaxel (75 mg/m²) (AT arm) versus doxorubicin (60 mg/m²) in combination with cyclophosphamide (600 mg/m²) (AC arm). 
U jednom velikom randomiziranom ispitivanju faze III u koje je bilo uključeno 429 ranije neliječenih bolesnika s metastatskom bolesti, primjenjivala se kombinacija doksorubicina (50 mg/m2) s docetakselom (75 mg/m2) (AT skupina) naspram kombinacije doksorubicina (60 mg/m2) i ciklofosfamida (600 mg/m2) (AC skupina).
• one 15 ml clear glass vial with a flip-off cap containing 2.88 ml concentrate and, 
• jednu prozirnu staklenu bočicu od 15 ml s "flip-off" zatvaračem koja sadržava 2,88 ml koncentrata i
Docetaxel must not be used in patients with baseline neutrophil count of <1,500 cells/mm3. 
Docetaksel se ne smije primjenjivati u bolesnika s početnim brojem neutrofila < 1500 stanica/mm3.
Subset Analyses-Adjuvant Therapy in Patients with Node-negative Breast Cancer Study (Intent-toTreat Analysis) 
Analiza podskupina - adjuvantno liječenje bolesnika s karcinomom dojke s negativnim limfnim čvorovima ("Intent-to-Treat" analiza)
• one 6 ml clear glass vial with a flip-off cap containing 0.72 ml concentrate and, 
• jednu prozirnu staklenu bočicu od 6 ml s "flip-off" zatvaračem koja sadržava 0,72 ml koncentrata i
Method of administration For instructions on preparation and administration of the product, see section 6.6. 
Za upute o pripremi i primjeni lijeka, vidjeti dio 6.6.
4.1.2 Using a syringe fitted with a needle, aseptically withdraw the entire contents of the solvent for Docetaxel Teva vial by partially inverting the vial. 
4.1.2 Rabeći štrcaljku s iglom, aseptički izvucite cjelokupni sadržaj otapala za Docetaksel Teva, djelomično okrećući bočicu otapala naopako.
Your doctor may change the dose and frequency of dosing depending on your blood tests, your general condition and your response to Docetaxel Teva. 
Vaš liječnik može mijenjati dozu i učestalost primjene lijeka ovisno o rezultatima krvnih pretraga,
In this study, 255 patients were randomised to treatment with docetaxel (75 mg/m2 as a 1 hour intravenous infusion every 3 weeks) and capecitabine (1,250 mg/m2 twice daily for 2 weeks followed by 1-week rest period). 
U ovoj studiji randomizirano je 255 bolesnika za liječenje docetakselom (75 mg/m2 u obliku jednosatne intravenske infuzije svaka 3 tjedna) i kapecitabinom (1250 mg/m2 dvaput dnevno tijekom 2 tjedna nakon čega slijedi 1 tjedan pauze).
• Overall response rate (ORR) was significantly higher in the AT arm versus AC arm, p=0.009. 
• Ukupna stopa terapijskog odgovora (ORR) bila je značajno veća u AT skupini naspram AC
Docetaxel Teva in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with: 
Karcinom dojke Docetaksel Teva u kombinaciji s doksorubicinom i ciklofosfamidom indiciran je za adjuvantno liječenje bolesnika s:
Acute myeloid leukemia and myelodysplastic syndrome have been reported (frequency uncommon) in pivotal clinical studies in breast cancer with TAC regimen. 
Akutna mijeloična leukemija i mijelodisplastični sindrom su prijavljeni (manje česta učestalost) u pivotalnim kliničkim ispitivanjima raka dojke u kojima se primjenjivao docetaksel,